Results 91 to 100 of about 55,621 (311)

Simvastatin Restores Uteroplacental Hemodynamics and Trophoblast Function in Obstetric Antiphospholipid Syndrome in a Placenta‐on‐a‐Chip Model

open access: yesAdvanced Healthcare Materials, EarlyView.
Simvastatin mitigates placental hypoperfusion in OAPS by ameliorating abnormal uteromaternal hemodynamics and enhancing trophoblast invasion via optimized endothelial cell interactions under pathological shear stress, as evidenced by results from a placenta‐on‐a‐chip platform.
Hongli Liu   +10 more
wiley   +1 more source

No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy [PDF]

open access: yes, 2018
We report on four patients with narcolepsy with cataplexy (NC), who were treated with high-dose intravenous immunoglobulins (IVIg). Although in some patients transient effects were seen of both objective (multiple sleep latency test and maintenance of ...
Bassetti, C.   +3 more
core  

Ferritin‐Doped Nanoparticles Triggered Tumor‐Specific Darkening for Enhanced Photothermal Tumor Ablation and Immune Activation

open access: yesAdvanced Healthcare Materials, EarlyView.
Ferritin‐doped hybrid nanoparticles triggered accurate tumor‐specific hemorrhage for enhanced in situ photothermal therapy and evoked anti‐tumor immunity. Notably, HFn/GA‐Fe specifically induced tumor hemorrhage 12 h after intravenous injection, resulting in visible color darkening. Through photoacoustic imaging, tumor vessels could be clearly observed
Haidong Zha   +7 more
wiley   +1 more source

Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness [PDF]

open access: yes, 2016
Sepsis is characterized by a complex immune response. In this study we aimed to provide a review of the mechanisms of action of immunoglobulin (Ig) related to sepsis and an updated meta-analysis of the clinical effectiveness of the Ig use in septic ...
Busani, Stefano   +4 more
core  

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? [PDF]

open access: yes, 2008
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, and recognition of their potential. It appears that the promise of the "magic bullet" has largely been realized.
Dimitrov, Dimiter S, Marks, James D
core   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

Thymoma complicated with myasthenia gravis and Good syndrome – a therapeutic conundrum: a case report

open access: yesJournal of Medical Case Reports, 2019
Background Thymomas are known to be associated with myasthenia gravis and Good syndrome. Good syndrome is the association of thymoma with combined B cell and T cell immunodeficiency. The combination of all three diseases has not been reported. We discuss
Shiran Paranavitane   +3 more
doaj   +1 more source

The Advent Of Cytomegalovirus Infection In HIV Infected Patients: A review [PDF]

open access: yes, 2004
Cytomegalovirus is considered as one among the long list of latent infections in humans that although normally controlled by the cellular immune response, gets activated after HIV infection takes its role on infecting the T4 lymphocytes. Clinical disease
Kirubakaran Isaac, Dr Sundar
core   +1 more source

Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases [PDF]

open access: yes, 2008
Background: Paraneoplastic neurological syndromes (PNS) are indirect remote effects of cancer on the nervous system, often associated with the presence of specific serum antibodies.
Hoffmann, L. A.   +10 more
core   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy